DelveInsight’s “Prurigo Nodularis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Prurigo Nodularis pipeline landscapes.
The report comprises Prurigo Nodularis pipelinedrug profiles, including clinical and non-clinical stage products. It also includes the Prurigo Nodularis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Prurigo Nodularis pipeline products.
Prurigo Nodularis Overview
Prurigo nodularis is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. Prurigo nodularis is accompanied by long-standing pruritus and is thought to develop as a reaction to repeated scratching in patients with Chronic Prurigo from various etiologies, including dermatological, systemic, infectious, and psychiatric.
Some of the key takeaways from the Prurigo Nodularis Pipeline Report:
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Menlo Therapeutics, Trevi Therapeutics, Galderma, Dupixent, Amagen, Kiniksa Pharmaceuticals, Maruho, etc., are developing therapies for the treatment of Prurigo Nodularis.
Emerging therapies such as Serlopitant, Nalbuphine ER, Nemolizumab, Sanofi/ Regeneron, Apremilast, KPL-716, M118103, are expected to have a significant impact on the Prurigo Nodularis market in the coming years.
Get an overview of pipeline landscape @ Prurigo Nodularis Clinical Trials Analysis
Prurigo Nodularis Pipeline Therapies along with Key Players:
Serlopitant :Menlo Therapeutics
Nalbuphine ER: Trevi Therapeutics
Nemolizumab: Galderma
Sanofi/ Regeneron:Dupixent
Apremilast: Amagen
KPL-716:Kiniksa Pharmaceuticals
M118103:Maruho
Scope of Prurigo Nodularis Pipeline Drug Insight
Coverage: Global
Major Players: Menlo Therapeutics, Trevi Therapeutics, Galderma, Dupixent, Amagen, Kiniksa Pharmaceuticals, Maruho, and others.
Pipeline Therapies: Serlopitant, Nalbuphine ER, Nemolizumab, Sanofi/ Regeneron, Apremilast, KPL-716, M118103, and others.
Table of Contents
1
Prurigo Nodularis Report Introduction
2
Prurigo Nodularis Executive Summary
3
4
Prurigo Nodularis-Analytical Perspective In-depth Commercial Assessment
5
Prurigo Nodularis Pipeline Therapeutics
6
Prurigo Nodularis Late Stage Products (Phase II/III)
7
Prurigo Nodularis Mid Stage Products (Phase II)
8
Prurigo Nodularis Early Stage Products (Phase I)
9
Prurigo Nodularis Preclinical Stage Products
10
Prurigo Nodularis Therapeutics Assessment
11
Prurigo Nodularis Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Prurigo Nodularis Key Companies
14
Prurigo Nodularis Key Products
15
Prurigo Nodularis Unmet Needs
16
Prurigo Nodularis Market Drivers and Barriers
17
Prurigo Nodularis Future Perspectives and Conclusion
18
Prurigo Nodularis Analyst Views
19
Appendix
20
About DelveInsight
Get a customized pipeline report @ Prurigo Nodularis Drugs Pipeline Report
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/